An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Plegridy

Chemical Namepeginterferon beta-1a
Dosage FormInjection (subcutaneous; 125mg/0.5mL, 63mg/0.5mL, 94mg/0.5mL)
Drug ClassModulators
SystemBlood
CompanyBiogen Inc.
Approval Year2014

Indication

  • For the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Last updated on 4/20/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Plegridy (peginterferon beta-1a) Prescribing Information2014Biogen Inc., Cambridge, MA
Document TitleYearSource
Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis.2020NICE
Document TitleYearSource
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.2018Multiple Sclerosis Journal